FOXO4-D-Retro-Inverso (DRI): Senolytics Peptide for Life Extension and Cellular Health
Discover the power of FOXO4-D-Retro-Inverso (DRI) custom peptide for advanced cellular rejuvenation and enhanced longevity.
Get a Quote & SampleProduct Core Value
FOXO4-D-Retro-Inverso (DRI) Custom Peptide
This pharmaceutical-grade peptide is engineered for its potent senolytic properties, targeting senescent cells to promote tissue homeostasis and combat aging effects. As a key player in custom peptide synthesis, it offers a promising avenue for life extension research.
- Explore the benefits of custom peptide synthesis FOXO4 DRI for targeted cellular therapies.
- Investigate FOXO4-D-Retro-Inverso peptide senolytics for advanced anti-aging solutions.
- Understand the mechanism of senescent cell apoptosis induction for healthier aging.
- Source pharmaceutical grade peptides for cutting-edge research and development.
Key Product Advantages
Enhanced Cellular Health
Leverage the senolytic capabilities of FOXO4-D-Retro-Inverso peptide to clear senescent cells, promoting improved tissue function and overall well-being.
Life Extension Potential
Utilize this peptide for life extension research, contributing to scientific advancements in combating age-related decline through senescent cell apoptosis induction.
High Purity and Quality
Benefit from pharmaceutical grade peptides with a purity exceeding 99%, ensuring reliability and efficacy in your research applications.
Key Applications
Senolytics Research
FOXO4-D-Retro-Inverso (DRI) custom peptide is a vital tool for researchers investigating senolytics and their role in clearing aged cells.
Life Extension Studies
This peptide for life extension serves as a critical component in studies aimed at understanding and promoting longevity.
Cellular Rejuvenation
The senescent cell apoptosis induction properties make it valuable for research into cellular rejuvenation and age-related disease mitigation.
Pharmaceutical Development
As a pharmaceutical intermediate, it supports the development of new therapeutic agents targeting aging and cellular senescence.